48 related articles for article (PubMed ID: 25450038)
1. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Geynisman DM; Hu JC; Liu L; Tina Shih YC
Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
[TBL] [Abstract][Full Text] [Related]
2. In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013.
Maroun R; Maunoury F; Benjamin L; Nachbaur G; Durand-Zaleski I
PLoS One; 2016; 11(9):e0162864. PubMed ID: 27649305
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
5. Health care costs among renal cancer patients using pazopanib and sunitinib.
Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
[TBL] [Abstract][Full Text] [Related]
7. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
8. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization.
Psutka SP; Kim SP; Gross CP; Van Houten H; Thompson RH; Abouassaly R; Weight C; Boorjian SA; Leibovich BC; Shah ND
Urology; 2015 Feb; 85(2):442-50. PubMed ID: 25623717
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma.
Calderón-Montaño JM; Guillén-Mancina E; Jiménez-Alonso JJ; Jiménez-González V; Burgos-Morón E; Mate A; Pérez-Guerrero MC; López-Lázaro M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555771
[TBL] [Abstract][Full Text] [Related]
10. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
Shih YT; Xu Y; Bradley C; Giordano SH; Yao J; Yabroff KR
J Natl Cancer Inst; 2022 Oct; 114(10):1392-1399. PubMed ID: 36099068
[TBL] [Abstract][Full Text] [Related]
11. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
12. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
[TBL] [Abstract][Full Text] [Related]
13. Characterizing online crowdfunding campaigns for patients with kidney cancer.
Thomas HS; Lee AW; Nabavizadeh B; Namiri NK; Hakam N; Martin-Tuite P; Rios N; Enriquez A; Mmonu NA; Cohen AJ; Breyer BN
Cancer Med; 2021 Jul; 10(13):4564-4574. PubMed ID: 34102000
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
[TBL] [Abstract][Full Text] [Related]
15. The impact of insurance status on the survival outcomes of patients with renal cell carcinoma.
Li Y; Zhu MX; Zhang B
Transl Androl Urol; 2020 Aug; 9(4):1678-1690. PubMed ID: 32944529
[TBL] [Abstract][Full Text] [Related]
16. Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
Liao KH; Ko BS; Chen LK; Hsiao FY
Clin Transl Sci; 2020 Nov; 13(6):1288-1297. PubMed ID: 32583962
[TBL] [Abstract][Full Text] [Related]
17. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
18. Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.
Redig J; Dalén J; Harmenberg U; Lindskog M; Ljungberg B; Lundstam S; Sandin R; Wahlgren T; Åkerborg Ö; Jakobsson M
Cancer Manag Res; 2019; 11():1289-1297. PubMed ID: 30799955
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Chien CR; Geynisman DM; Kim B; Xu Y; Shih YT
Pharmacoeconomics; 2019 Mar; 37(3):301-331. PubMed ID: 30467701
[TBL] [Abstract][Full Text] [Related]
20. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
